Mannkind Corp (MNKD)

MannKind Corporation (MNKD) stock was sliding after the bell following the company's quarterly earnings report, which included a year-over-year Afrezza revenue growth of 142%.

Don’t Buy MannKind Corporation Stock Under Any Circumstances

By Chris Fraley, InvestorPlace Contributor Feb 12, 2018

With a depressed share price, sales set to double this year, and a traditionally high-growth sector, it can be tempting to view MannKind Corp. (MNKD) as a bargain. Don’t make that mistake.

Is MannKind Corporation Stock Really Worth the Risk?

By Joseph Hargett, InvestorPlace Contributor Jan 26, 2018

Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?

Metrics for Earnings Visibility Keep Mannkind (MNKD) a Sell at recent price of $3.8

By Portfolio Grader Jan 26, 2018

The Sell recommendation for Mannkind Corp is the outcome of an analytical process that is proprietary which generated conclusions that were above average in 2 areas: an economic sector rated above average in attractiveness, and a mathematical computation of risk/reward that is better than average; and produced below average results in 4 areas: an industry group rated below average in attractiveness, a ranking in the company's sector that is in the middle third, ranking in the company's industry group that is in the middle third-below average, and analytical scoring that is well below average.

5 Giant-Slaying Small-Cap Stocks to Buy

By John Kilhefner, Managing Editor, InvestorPlace.com Oct 9, 2017

Small-cap stocks with strong earnings growth and down-to-earth valuations are performing better than even the largest of blue chips.

Friday’s Vital Data: MannKind Corporation (MNKD), Apple Inc. (AAPL) and Netflix, Inc. (NFLX)

By Joseph Hargett, InvestorPlace Contributor Oct 6, 2017

MannKind (MNKD) options soar on Afrezza label win, Apple (AAPL) is plagued by iPhone 8 battery bloating, while Netflix (NFLX) raised prices.

MannKind Corporation (MNKD) Shares Up Despite Earnings Miss

By William White, InvestorPlace Writer Aug 8, 2017

MannKind (MNKD) stock was up on Tuesday despite the company reporting an earnings and revenue miss in its second quarter of 2017.

9 Companies That Might Not Survive to See 2018

By Vince Martin, InvestorPlace Contributor Jun 30, 2017

These nine companies are either on the brink of Chapter 11 or already in bankruptcy proceedings. Either way, things look grim.

MannKind Corporation (MNKD) Stock Slammed Despite Smaller Q1 Losses

By InvestorPlace Staff May 11, 2017

Just days after announcing a breakthrough distribution pact, MNKD delivered news of smaller first-quarter losses.

MannKind Corporation (MNKD) Shares Continue to Surge on ‘One Drop’ News

By William White, InvestorPlace Writer May 10, 2017

MannKind (MNKD) stock is still on the rise following the announcement of its deal with One Drop and speculation of a sale.

The 7 WORST Stocks to Buy Right Now

By Vince Martin, InvestorPlace Contributor Mar 27, 2017

These seven worst stocks to buy right now seem likely to move downward, no matter what the stock market does from here.

MannKind Corporation (MNKD) Stock Sinks on Reverse Stock Split Plans

By Karl Utermohlen, InvestorPlace Writer Mar 3, 2017

MannKind Corporation (MNKD) shares are down as the company approved a reverse split that will reduce from 700 million to 140 million shares.

MannKind Corporation (MNKD) Stock Is a Lost Cause After Q3 Earnings

By James Brumley, InvestorPlace Feature Writer Nov 9, 2016

MannKind (MNKD), down 90% over the past couple of years, is still fighting an uphill, un-winnable battle. MNKD stock is nearly out of time.

Thursday’s Vital Data: Apple Inc. (AAPL), Micron Technology, Inc. (MU) and MannKind Corporation (MNKD)

By Joseph Hargett, InvestorPlace Contributor Sep 8, 2016

Wall Street yawns at Apple (AAPL) iPhone event, Micron (MU) rides DRAM projections and MannKind (MNKD) options bet big on Mylan (MYL) EpiPen rival.

MannKind Corporation (MNKD) Working to Take on Mylan’s EpiPen

By ValueWalk Sep 6, 2016

MannKind (MNKD) is in the early stages of developing an inhalable form of epinephrine, which could help it take market share from the injectable version.